Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Pathikrit Bose

Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.

Kenvue (KVUE) could really use some good news. The Johnson & Johnson (JNJ) spinoff faced longlasting troubles regarding its talc-based baby powder products, including allegations that they caused cancer and related lawsuits. 

Now, the consumer health giant faces new troubles as President Donald Trump has accused its Tylenol product of increasing autism when used in pregnancy. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.